Development of NIPAAm-PEG acrylate polymeric nanoparticles for co-delivery of paclitaxel with ellagic acid for the treatment of breast cancer

Suruchi Suri; Mohd Aamir Mirza; Md Khalid Anwer; Abdullah S. Alshetaili; Saad M. Alshahrani; Farhan Jalees Ahmed; Zeenat Iqbal

doi:10.1515/polyeng-2018-0169

Development of NIPAAm-PEG acrylate polymeric nanoparticles for co-delivery of paclitaxel with ellagic acid for the treatment of breast cancer

Suruchi Suri, Mohd Aamir Mirza, Md Khalid Anwer, Abdullah S. Alshetaili, Saad M. Alshahrani, Farhan Jalees Ahmed, Zeenat Iqbal

Pharmaceutics

Jamia Hamdard University

Research output: Contribution to journal › Article › peer-review

8 Scopus citations

Abstract

The aim of the current study was to develop a dual-loaded core shell nanoparticles encapsulating paclitaxel (PTX) and ellagic acid (EA) by membrane dialysis method. Based on particle size, polydispersity index (PDI), and entrapment efficiency, the dual drug-loaded nanoparticles (F2) was optimized. The optimized nanoparticles (F2) showed a particle size of 140±2 nm and a PDI of 0.23±3. The size and the morphology were confirmed by transmission electron microscopy (TEM) and found agreement with the results of dynamic light scattering. The entrapment efficiencies of total drug (PTX and EA), PTX, and EA in the nanoparticles (F2) were measured as 80%, 62.3%, and 37.7%, respectively. The in vitro release profile showed a controlled release pattern for 48 h. A higher cytotoxicity was observed with nanoparticles (F2) in comparison to free PTX. The results revealed that co-delivery of PTX and EA could be used for its oral delivery for the effective treatment of breast cancer.

Original language	English
Pages (from-to)	271-278
Number of pages	8
Journal	Journal of Polymer Engineering
Volume	39
Issue number	3
DOIs	https://doi.org/10.1515/polyeng-2018-0169
State	Published - 1 Mar 2019

Keywords

core-shell nanoparticle
ellagic acid
MCF-7
MTT assay
paclitaxel

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1515/polyeng-2018-0169

Cite this

@article{581d9728bd1b47dd949bb0b9ab4befe8,

title = "Development of NIPAAm-PEG acrylate polymeric nanoparticles for co-delivery of paclitaxel with ellagic acid for the treatment of breast cancer",

abstract = "The aim of the current study was to develop a dual-loaded core shell nanoparticles encapsulating paclitaxel (PTX) and ellagic acid (EA) by membrane dialysis method. Based on particle size, polydispersity index (PDI), and entrapment efficiency, the dual drug-loaded nanoparticles (F2) was optimized. The optimized nanoparticles (F2) showed a particle size of 140±2 nm and a PDI of 0.23±3. The size and the morphology were confirmed by transmission electron microscopy (TEM) and found agreement with the results of dynamic light scattering. The entrapment efficiencies of total drug (PTX and EA), PTX, and EA in the nanoparticles (F2) were measured as 80\%, 62.3\%, and 37.7\%, respectively. The in vitro release profile showed a controlled release pattern for 48 h. A higher cytotoxicity was observed with nanoparticles (F2) in comparison to free PTX. The results revealed that co-delivery of PTX and EA could be used for its oral delivery for the effective treatment of breast cancer.",

keywords = "core-shell nanoparticle, ellagic acid, MCF-7, MTT assay, paclitaxel",

author = "Suruchi Suri and Mirza, \{Mohd Aamir\} and Anwer, \{Md Khalid\} and Alshetaili, \{Abdullah S.\} and Alshahrani, \{Saad M.\} and Ahmed, \{Farhan Jalees\} and Zeenat Iqbal",

note = "Publisher Copyright: {\textcopyright} 2019 Walter de Gruyter GmbH, Berlin/Boston.",

year = "2019",

month = mar,

day = "1",

doi = "10.1515/polyeng-2018-0169",

language = "English",

volume = "39",

pages = "271--278",

journal = "Journal of Polymer Engineering",

issn = "0334-6447",

publisher = "Walter de Gruyter GmbH",

number = "3",

}

TY - JOUR

T1 - Development of NIPAAm-PEG acrylate polymeric nanoparticles for co-delivery of paclitaxel with ellagic acid for the treatment of breast cancer

AU - Suri, Suruchi

AU - Mirza, Mohd Aamir

AU - Anwer, Md Khalid

AU - Alshetaili, Abdullah S.

AU - Alshahrani, Saad M.

AU - Ahmed, Farhan Jalees

AU - Iqbal, Zeenat

PY - 2019/3/1

Y1 - 2019/3/1

N2 - The aim of the current study was to develop a dual-loaded core shell nanoparticles encapsulating paclitaxel (PTX) and ellagic acid (EA) by membrane dialysis method. Based on particle size, polydispersity index (PDI), and entrapment efficiency, the dual drug-loaded nanoparticles (F2) was optimized. The optimized nanoparticles (F2) showed a particle size of 140±2 nm and a PDI of 0.23±3. The size and the morphology were confirmed by transmission electron microscopy (TEM) and found agreement with the results of dynamic light scattering. The entrapment efficiencies of total drug (PTX and EA), PTX, and EA in the nanoparticles (F2) were measured as 80%, 62.3%, and 37.7%, respectively. The in vitro release profile showed a controlled release pattern for 48 h. A higher cytotoxicity was observed with nanoparticles (F2) in comparison to free PTX. The results revealed that co-delivery of PTX and EA could be used for its oral delivery for the effective treatment of breast cancer.

AB - The aim of the current study was to develop a dual-loaded core shell nanoparticles encapsulating paclitaxel (PTX) and ellagic acid (EA) by membrane dialysis method. Based on particle size, polydispersity index (PDI), and entrapment efficiency, the dual drug-loaded nanoparticles (F2) was optimized. The optimized nanoparticles (F2) showed a particle size of 140±2 nm and a PDI of 0.23±3. The size and the morphology were confirmed by transmission electron microscopy (TEM) and found agreement with the results of dynamic light scattering. The entrapment efficiencies of total drug (PTX and EA), PTX, and EA in the nanoparticles (F2) were measured as 80%, 62.3%, and 37.7%, respectively. The in vitro release profile showed a controlled release pattern for 48 h. A higher cytotoxicity was observed with nanoparticles (F2) in comparison to free PTX. The results revealed that co-delivery of PTX and EA could be used for its oral delivery for the effective treatment of breast cancer.

KW - core-shell nanoparticle

KW - ellagic acid

KW - MCF-7

KW - MTT assay

KW - paclitaxel

UR - http://www.scopus.com/inward/record.url?scp=85060386709&partnerID=8YFLogxK

U2 - 10.1515/polyeng-2018-0169

DO - 10.1515/polyeng-2018-0169

M3 - Article

AN - SCOPUS:85060386709

SN - 0334-6447

VL - 39

SP - 271

EP - 278

JO - Journal of Polymer Engineering

JF - Journal of Polymer Engineering

IS - 3

ER -

Development of NIPAAm-PEG acrylate polymeric nanoparticles for co-delivery of paclitaxel with ellagic acid for the treatment of breast cancer

Abstract

Keywords

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this